In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Innate Immunotherapeutics Limited

http://www.innateimmunotherapeutics.com

Latest From Innate Immunotherapeutics Limited

Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Price Wins Confirmation As US Health Secretary; Verma On Deck For CMS Hearing

Senators voted 52 to 47 to confirm Rep. Tom Price, R-Ga., as Health and Human Services secretary, where he will be a key leader implementing reversals to the Affordable Care Act. Meanwhile, Trump’s pick to lead the Medicare agency, Seema Verma, faces a confirmation hearing in the Senate Feb. 16.

Policy Legislation

Senate Finance Advances Tom Price HHS Confirmation, Sans Democrats

An all-Republican Senate Finance panel changed the committee’s rules Feb. 1 and voted 14-0 to advance HHS Secretary nominee Tom Price’s, R-Ga., confirmation to the full Senate, after the panel’s Democrats, led by ranking member Ron Wyden of Oregon, boycotted Price’s confirmation markup for a second day due to lingering questions about Price’s investments in Innate Immunotherapeutics stocks, Wyden said.

Policy Legislation

HHS Nominee Vote Delayed By Senate Dem Boycott

Senate Finance Committee Ranking Member Ron Wyden led other panel Democrats in boycotting a planned Jan. 31 vote on the confirmation of Rep. Tom Price as HHS Secretary. Wyden said the nominee "misled the public" and held back information on discounted shares of an Australian biomedical firm he bought. Committee Chair Orrin Hatch, R-Utah, was surprised by the setback to President Trump's nominee, and swore to bring Senate Democrats back to the committee to "do their job.”

Policy & Regulation Policy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • Amplia Therapeutics Pty Ltd
    • Innate Immunotherapeutics Ltd.
    • Virionyx Corporation
UsernamePublicRestriction

Register